|Application ||WB, IHC, E|
|Description||This gene encodes a member of the tyrosine protein kinase family. The encoded protein plays a critical role in angiogenesis and blood vessel stability by inhibiting angiopoietin 1 signaling through the endothelial receptor tyrosine kinase Tie2. Ectodomain cleavage of the encoded protein relieves inhibition of Tie2 and is mediated by multiple factors including vascular endothelial growth factor. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.|
|Immunogen||Purified recombinant fragment of human TIE1 (AA: 385-607) expressed in E. Coli.|
|Formulation||Purified antibody in PBS with 0.05% sodium azide.|
|Other Names||Tyrosine-protein kinase receptor Tie-1, 126.96.36.199, TIE1, TIE|
WB~~1/500 - 1/2000
IHC~~1/200 - 1/1000
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||TIE1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transmembrane tyrosine-protein kinase that may modulate TEK/TIE2 activity and contribute to the regulation of angiogenesis.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Specifically expressed in developing vascular endothelial cells|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This locus encodes the transforming growth factor (TGF)-beta type III receptor. The encoded receptor is a membrane proteoglycan that often functions as a co-receptor with other TGF-beta receptor superfamily members. Ectodomain shedding produces soluble TGFBR3, which may inhibit TGFB signaling. Decreased expression of this receptor has been observed in various cancers. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. ; ; ;
1. Int J Oncol. 2007 Oct;31(4):893-7. 2. Cancer. 2002 Mar 1;94(5):1517-21.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.